Contrasting Pluri (NASDAQ:PLUR) and ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics (NASDAQ:ADMA) and Pluri (NASDAQ:PLUR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Institutional & Insider Ownership

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 3.7% of ADMA Biologics shares are held by insiders. Comparatively, 10.2% of Pluri shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for ADMA Biologics and Pluri, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0	0	3	1	3.25
Pluri	0	0	0	0	N/A

ADMA Biologics presently has a consensus price target of $15.50, suggesting a potential downside of 20.02%. Given ADMA Biologics’ higher probable upside, research analysts clearly believe ADMA Biologics is more favorable than Pluri.

Valuation & Earnings

This table compares ADMA Biologics and Pluri”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$258.21 million	17.49	-$28.24 million	($0.02)	-969.00
Pluri	$330,000.00	99.12	-$20.89 million	($4.13)	-1.45

Pluri has lower revenue, but higher earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ADMA Biologics and Pluri’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	10.53%	38.79%	17.35%
Pluri	-6,341.03%	-493.74%	-75.93%

Risk and Volatility

ADMA Biologics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Pluri has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500.

Summary

ADMA Biologics beats Pluri on 9 of the 13 factors compared between the two stocks.

About ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

About Pluri

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.